Products with Neuroprotection Bioactivity
Explore BioCrick products associated with Neuroprotection biological activity, including catalog numbers, product names and available bioactivity information.
Neuroprotection Bioactivity Products
| Cat. No. | Product Name |
|---|---|
| BCN1011 | Asiaticoside |
| Asiaticoside, a biochemical modulator, which has antioxidant, anti-inflammatory, antipyretic, anxiolytic-like, anti-gastric ulcers, hepatoprotective, and antidepressant-like effects, it also exhibits significant wound healing activity in normal as well as delayed healing models. Asiaticoside suppressed collagen expression and TGF-β/Smad signaling through inducing Smad7 and inhibiting TGF-βRI and TGF-βRII in keloid fibroblasts. It and its derivatives can be regarded as reasonable candidates for a therapeutic Alzheimer's disease drug that protects neurons from Abeta toxicity. | |
| BCN1012 | Madecassoside |
| Madecassoside is a mechanism-based inhibitor of CYP2C19 and CYP3A4, which has antioxidant, anti-inflammatory, anti-apoptosis, wound-healing, and neuroprotective activities, It may have cardioprotective effects in LPS-mediated through inhibition of ERK, p38, and NF-κB activity, it inhibited the pro-inflammatory mediators, including COX-2 expression, PGE2 production, TNF-αand IL-6 levels and the up-regulation anti-inflammatory molecule IL-10. | |
| BCN1021 | Schizandrin A |
| Schisandrin A , an agonist of the adiponectin receptor 2 (AdipoR2) with the IC50 value of 3.5 μM, has neuroprotective, anti-inflammatory, liver-protective, antitumor, and antioxidant activities. It alleviated microglia-mediated neuroinflammation injury through inhibiting the TRAF6-IKKβ-NF-κB and Jak2-Stat3 signaling pathways. It inhibited CYP3A activity with an IC50 of 6.60 μM and Ki of 5.83 μM, respectively. | |
| BCN1031 | Ligustilide |
| Ligustilide possesses neuroprotective, vasorelaxation, antinociceptive and anti-inflammatory activities, it blocked the activation of MAPKs/IKK and the downstream transcription factors AP-1 and NF-κB. It has the potential to be developed into an effective drug for the treatment of various pain syndromes including primary dysmenorrhoea. | |
| BCN1037 | Punicalagin |
| Punicalagin has antifungal , antiviral, anti-atherosclerotic, hepatoprotective , anti-obesity., antiproliferative, anti-apoptotic, anti-inflammatory, and antioxidant effects. It can suppress the phosphorylation of MAPK including p38, c-JNK, and ERK, it also has potently inhibiting the activity of fatty acid synthase with half-inhibitory concentration values (IC 50 ) of 4.50μM. | |


